Ipsen in Ireland
Development and manufacturing
The Dublin site, which opened in 1989, is the Group’s center for the production and development of peptides (lanreotide and triptorelin). In addition to the development of peptide active ingredients, Dublin also has responsibility for developing small molecule active ingredients, in particular with regard to the development of manufacturing processes, large-scale manufacturing, quality control and analytic development.
16 July 2015 - Paris (France)
Ipsen announces FDA approval of Dysport® (abobotulinumtoxinA) for injection in the treatment of upper limb spasticity in adults in the…